Dianthus Therapeutics is a biotechnology company focused on developing innovative therapies for patients with autoimmune diseases and cancer. Its core products include monoclonal antibodies and other biologics targeting specific immune pathways. The company primarily generates revenue through research collaborations and potential future product sales as it advances its pipeline of drug candidates.
The investment profile of Dianthus Therapeutics is more aligned with growth investors due to its focus on developing new therapies and the potential for significant revenue growth as products progress through clinical stages. The company does not currently offer dividends, making it less suitable for income-focused investors.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-26 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-09-18 | Sell | Hold | Weak momentum and high risk; uncertain outlook. |
| 2026-09-11 | Hold | Sell | Weak momentum and high risk; uncertain growth outlook. |
| 2026-09-05 | — | Hold | Strong revenue growth, but negative EPS and uncertainty. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-08-06 | H.C. Wainwright | Target Raised | 130 → 158 | 112.5 |
| 2026-08-05 | Wedbush | Target Raised | 105 → 122 | 111.27 |
| 2026-08-05 | Raymond James | Target Raised | — → 131 | 110.4 |
| 2026-06-10 | Jefferies | Target Raised | 110 → 132 | 76.42 |
| 2026-05-11 | Evercore ISI | Target Lowered | 122 → 120 | 88.45 |
| 2026-05-06 | Raymond James | Target Raised | 123 → 125 | 87.829 |
| 2026-04-08 | Wolfe Research | Update | — → 98 | 87.48 |
| 2026-03-09 | UBS | Target Raised | 81 → 98 | 79.23 |
| 2026-03-09 | Jefferies | Target Raised | — → 98 | 79.23 |
| 2026-03-09 | Robert W. Baird | Target Raised | 67 → 132 | 79.23 |
